Active Ingredient History
Somatostatin, also known as growth hormone-inhibiting hormone (GHIH) or by several other names, is a peptide hormone that regulates the endocrine system and affects neurotransmission and cell proliferation via interaction with G protein-coupled somatostatin receptors and inhibition of the release of numerous secondary hormones. Somatostatin inhibits insulin and glucagon secretion. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Carcinoid Tumor (Phase 2)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Islet Cell (Phase 2)
Diabetic Retinopathy (Phase 2/Phase 3)
End Stage Liver Disease (Phase 4)
Esophageal and Gastric Varices (Phase 4)
Gallbladder Neoplasms (Phase 3)
General Surgery (Phase 3)
Healthy Volunteers (Phase 4)
Hemorrhage (Phase 4)
Hypertension, Portal (Phase 4)
Hypoglycemia (Phase 1)
Intestinal Diseases (Phase 4)
Intestinal Neoplasms (Phase 4)
Liver Cirrhosis (Phase 4)
Liver Failure (Phase 3)
Neuroendocrine Tumors (Phase 2)
Pancreatic Diseases (Phase 2/Phase 3)
Pancreatic Fistula (Phase 4)
Pancreatic Neoplasms (Phase 3)
Pancreatitis (Phase 3)
Pancreatitis, Acute Necrotizing (Phase 4)
Peptic Ulcer (Phase 2)
Polycystic Kidney, Autosomal Dominant (Phase 3)
Prostatic Neoplasms (Phase 1)
Stomach Neoplasms (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue